Primary Health Care Limited

primarycareers.com.au

At Primary Health Care, our purpose is to help all Australians be healthy and well. Our extensive network of medical centers with General Practice, pathology labs, diagnostic imaging and more offer patients the convenience of seamless medical services, whilst Healthcare Practitioners enjoy working in unique multi-disciplinary environments where they can pursue clinical excellence and innovative care. We are committed to shaping the future of Australian healthcare. From a single medical centre in 1985, our passion for delivering total care has seen us become the choice of over 2 million Australian patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

NARRATIVA RAISES $1.3M TO HELP PHARMA COMPANIES ACCELERATE THE FDA DRUG APPROVAL PROCESS

Narrativa | May 19, 2021

news image

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). Th...

Read More

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

news image

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

Business Insights

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

news image

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Read More

GRIFOLS TO ACQUIRE MONTREAL-BASED PLASMA FRACTIONATION FACILITY AND TWO PURIFICATION FACILITIES FOR US$460 MILLION

Grifols, Green Cross Corporation | July 21, 2020

news image

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expa...

Read More
news image

Pharmacy Market

NARRATIVA RAISES $1.3M TO HELP PHARMA COMPANIES ACCELERATE THE FDA DRUG APPROVAL PROCESS

Narrativa | May 19, 2021

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). Th...

Read More
news image

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

news image

Business Insights

TEVA REACHES AGREEMENT WITH TEXAS TO SETTLE THE STATE’S OPIOID-RELATED CLAIMS

Teva Pharmaceuticals | February 08, 2022

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state’s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan®, valued at $75 million over 10 years. “Expan...

Read More
news image

GRIFOLS TO ACQUIRE MONTREAL-BASED PLASMA FRACTIONATION FACILITY AND TWO PURIFICATION FACILITIES FOR US$460 MILLION

Grifols, Green Cross Corporation | July 21, 2020

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us